
CLAIMS

1. Use of a compound represented by formula (I):



(I)

or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment ~~or prevention~~ of a cell proliferative disorder,

wherein the medicament is to be used in such a manner that:

(a) said compound or salt is <u>to be</u> administered twice weekly for 3 weeks,

(b) administration of said compound or salt is <u>to be</u> paused for the following 1 week, and

(c) steps (a) and (b) are <u>to be</u> subsequently repeated at least once<u>,</u>

<u>wherein the cell proliferative disorder is cancer</u>.

2. The use according to claim 1, which is use of a potassium salt of a compound represented by formula (I).

~~3. The use according to claim 1 or 2, wherein the cell proliferative disorder is cancer.~~

4<u>3</u>. The use according to ~~any one of claims 1 to 3~~ <u>claim 1 or 2</u>,

wherein the cell proliferative disorder is a KRAS mutant cancer.

~~5~~4. The use according to any one of claims 1 to 4~~3~~, wherein the cell proliferative disorder is a solid cancer.

~~6~~5. The use according to any one of claims 1 to ~~5~~4, wherein the dose per administration in step (a) is 3.2 mg.

~~7~~6. The use according to claim ~~6~~5, wherein the medicament is to be used in such a manner that prior to step (a):

(1) said compound or salt is to be administered twice weekly at a dose of 3.2 mg per administration; or

(2)

(2a) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 4 mg per administration,

(2b) administration of said compound or salt is to be paused for the following 1 week, and

(2c) steps (2a) and (2b) are to be subsequently repeated at least once.

~~8~~7. The use according to claim ~~7~~6, wherein the medicament is to be used in such a manner that prior to step (1) or (2), said compound or salt is to be administered twice weekly at a dose of 4 mg per administration.

~~9~~8. The use according to any one of claims 1 to ~~5~~4:

wherein the medicament is to be used in such a manner that:

(A) first, said compound or salt is to be administered twice weekly at a dose of 4 mg per administration,

(B1) next, said compound or salt is to be administered twice weekly at a dose of 3.2 mg per administration,

(C) after which:

(Ca) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 3.2 mg per administration,

(Cb) administration of said compound or salt is to be paused for the following 1 week, and

(Cc) steps (Ca) and (Cb) are to be subsequently repeated at least once; or

wherein the medicament is to be used in such a manner that:

(A) first, said compound or salt is to be administered twice weekly at a dose of 4 mg per administration,

(B2) following which:

(B2a) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 4 mg per administration,

(B2b) administration of said compound or salt is to be paused for the following 1 week, and

(B2c) steps (B2a) and (B2b) are to be subsequently repeated at least once; or

wherein the medicament is to be used in such a manner that:

(A) first, said compound or salt is to be administered twice weekly at a dose of 4 mg per administration,

(B2) following which:

(B2a) said compound or salt is to be administered twice weekly

for 3 weeks at a dose of 4 mg per administration,

(B2b) administration of said compound or salt is to be paused for the following 1 week, and

(B2c) steps (B2a) and (B2b) are to be subsequently repeated at least once,

(C) after which:

(Ca) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 3.2 mg per administration,

(Cb) administration of said compound or salt is to be paused for the following 1 week, and

(Cc) steps (Ca) and (Cb) are to be subsequently repeated at least once.

~~10~~9. The use according to any one of claims 1 to 4~~2~~3, wherein the cell proliferative disorder is multiple myeloma.

~~11~~10. The use according to claim ~~10~~9, wherein the dose per administration in step (a) is 4 mg.

~~12~~11. The use according to claim ~~10~~9 or ~~11~~10, wherein the cell proliferative disorder is an NRAS mutant cancer.

~~13~~12. The use according to any one of claims ~~10~~9 to ~~12~~11, wherein the medicament is to be used in combination with dexamethasone, and wherein the medicament is to be used in such a manner that said compound or salt is to be administered before, simultaneously with or

after administration of dexamethasone.

~~14~~13. The use according to claim ~~13~~12, wherein dexamethasone is to be administered once weekly at a dose of 20 mg per administration.

~~15~~14. The use according to any one of claims 1 to ~~14~~13, wherein the administration of said compound or salt is oral administration.